Validation of a rat in vivo [3H]M100907 binding assay to determine a translatable measure of 5-HT2A receptor occupancy

European Journal of Pharmacology

Volumn 591, Issue 1-3, 2008, Pages 136-141

  Knauer, Christopher S ^a   Campbell, Jeffrey E ^a   Galvan, Betsy ^a   Bowman, Christopher ^a   Osgood, Sarah ^a   Buist, Susan ^a   Buchholz, Lisa ^a   Henry, Brian ^b   Wong, Erik H F ^a   Shahid, Mohammed ^b   Grimwood, Sarah ^a  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

5 HT2A receptor; Antipsychotics; In vivo binding; Receptor occupancy

Indexed keywords

ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; KETANSERIN; OLANZAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; TRITIUM; VOLINANSERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG INHIBITION; DRUG POTENCY; HISTOPATHOLOGY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SEROTONINERGIC SYSTEM; VALIDATION PROCESS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HUMANS; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; TISSUE DISTRIBUTION;

EID: 48749125138     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.063     Document Type: Article

References (26)

1. Bhatt J., Subbaiah G., and Singh S. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Communications in Mass Spectrometry 20 (2006) 2109-2114
2. Brunner F., Bhargava V., Howard D., and Offord S.J. The safety, tolerability, pharmacokinetics and pharmacodynamics of a selective 5-HT2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers. Eur. Neuropsychopharmacol. 8 (1998) S241-S242
3. Carlsson M.L. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis. J. Neural. Transm. Gen. Sect. 100 (1995) 225-237
4. Chaki S., Funakoshi T., Yoshikawa R., Okuyama S., Kumagai T., Nakazato A., Nagamine M., and Tomisawa K. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats. Neuropharmacology 38 (1999) 1185-1194
5. Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., and Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J. Clin. Psychopharmacol. 15 (1995) 19S-23S
6. Grunder G., Yokoi F., Offord S.J., Ravert H.T., Dannals R.F., Salzmann J.K., Szymanski S., Wilson P.D., Howard D.R., and Wong D.F. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17 (1997) 175-185
7. Institute of Laboratory Animal Resources. Guide for the care and use of laboratory animals. In: Council N.R. (Ed). NIH Publication No. 85-23 (1985), National Academy Press, Washington, D.C.
8. Ito H., Nyberg S., Halldin C., Lundkvist C., and Farde L. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med 39 (1998) 208-214
9. Jentsch J.D., Shahid M., Wong E.H.F., and Roth R.H. Asenapine improves cognitive function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine. Schizophr. Res. 81 (2006) 85
10. Kapur S., Zipursky R.B., and Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156 2 (1999) 286-293
11. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., van Giersbergen P.L., McCloskey T.C., Johnson M.P., McCarty D.R., Poirot M., Senyah Y., Siegel B.W., and Widmaier C. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277 (1996) 968-981
12. 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 21 (1982) 301-314
13. 3H]MDL 100,907. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1997) 446-454
14. Lundkvist C., Halldin C., Ginovart N., Nyberg S., Swahn C.G., Carr A.A., Brunner F., and Farde L. [11C]MDL 100907, a radioligand for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci. 58 (1996) PL187-PL192
15. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
16. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., and Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31 (2006) 1854-1863
17. Nordstrom A.L., Farde L., and Halldin C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl.) 110 (1993) 365-367
18. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., and Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry 152 (1995) 1444-1449
19. Nyberg S., Farde L., Eriksson L., Halldin C., and Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl.) 110 (1993) 265-272
20. Potkin S.G., Cohen M., and Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry 8 (2007) 1195-1205
21. Schmidt C.J., Sorensen S.M., Kehne J.H., Carr A.A., and Palfreyman M.G. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 56 (1995) 2209-2222
22. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124 (1996) 57-73
23. Schotte A., Janssen P.F., Megens A.A., and Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631 (1993) 191-202
24. Shahid, M., Walker, G.B., Zorn, S.H., Wong, E.H.F., in press. Asenapine: a Novel Psychopharmacologic Agent with a Unique Human Receptor Signature. J. Psychopharmacol. [February 28, 2008, Electronic publication ahead of print].
25. Sorensen S.M., Kehne J.H., Fadayel G.M., Humphreys T.M., Ketteler H.J., Sullivan C.K., Taylor V.L., and Schmidt C.J. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266 (1993) 684-691
26. Zhang W., and Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 141 (1999) 267-278